Longeveron (LGVN) Stock
Clinical stage biotech developing cell therapies for aging. Here's the price, business snapshot, and what's worth knowing about Longeveron in August 2026.
Longeveron Inc (LGVN) is a clinical-stage biotechnology company with a market capitalisation of about $17.7 million, focused on developing allogeneic cell‑based therapies aimed at ageing‑related conditions and organ injury. Investors should know this is an early‑stage, science‑driven business: value is highly dependent on clinical trial outcomes, regulatory milestones and potential partnerships or licensing deals. The company typically has limited revenue and may need additional financing, which can dilute shareholders or affect the share price. Positive trial results or strategic collaborations can materially re‑rate the stock, while setbacks, trial delays or funding shortfalls can lead to sharp declines. Follow cash runway, upcoming readouts, management commentary and regulatory interactions for signals. This summary is educational only and not personal financial advice; biotech investing is high risk and volatile — values can fall as well as rise.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Longeveron Inc's stock with a target price of $11.72, indicating strong growth potential.
Financial Health
Longeveron Inc shows moderate revenue and strong profit margins, with healthy cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Pipeline Focus
The company’s valuation is closely tied to its pipeline and trial readouts, which can create significant upside if results are favourable, though outcomes are uncertain.
High Volatility Risk
Small‑cap biotech shares often move sharply on news and financings; investors should expect high volatility and potential dilution from future capital raises.
Partnership Potential
Strategic collaborations or licensing deals can de‑risk programmes and unlock value, but final deals depend on data and negotiating progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
